ES2071681T3 - Compuestos macrociclicos. - Google Patents

Compuestos macrociclicos.

Info

Publication number
ES2071681T3
ES2071681T3 ES89900628T ES89900628T ES2071681T3 ES 2071681 T3 ES2071681 T3 ES 2071681T3 ES 89900628 T ES89900628 T ES 89900628T ES 89900628 T ES89900628 T ES 89900628T ES 2071681 T3 ES2071681 T3 ES 2071681T3
Authority
ES
Spain
Prior art keywords
represent
alkyl
compounds
groups including
carbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89900628T
Other languages
English (en)
Inventor
Martin Edward Cooper
David Keith Donald
David Norman Hardern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fisons Ltd
Original Assignee
Fisons Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878728821A external-priority patent/GB8728821D0/en
Priority claimed from GB878728820A external-priority patent/GB8728820D0/en
Priority claimed from GB888803375A external-priority patent/GB8803375D0/en
Priority claimed from GB888803371A external-priority patent/GB8803371D0/en
Priority claimed from GB888803372A external-priority patent/GB8803372D0/en
Priority claimed from GB888803373A external-priority patent/GB8803373D0/en
Priority claimed from GB888803377A external-priority patent/GB8803377D0/en
Priority claimed from GB888803370A external-priority patent/GB8803370D0/en
Priority claimed from GB888803374A external-priority patent/GB8803374D0/en
Priority claimed from GB888809174A external-priority patent/GB8809174D0/en
Priority claimed from GB888817624A external-priority patent/GB8817624D0/en
Priority claimed from GB888818426A external-priority patent/GB8818426D0/en
Application filed by Fisons Ltd filed Critical Fisons Ltd
Publication of ES2071681T3 publication Critical patent/ES2071681T3/es
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Steroid Compounds (AREA)

Abstract

Un procedimiento para producir un compuesto de la fórmula I, **fórmula** en donde cada par vecino de sustituyentes [R1 y R2], [R3 y R4] y [R5 y R 6 ], independientemente: a) representan dos átomos de hidrógeno vecinos o b) forman un segundo enlace entre los átomos de carbono vecinos a los que están unidos; R7 representa H, OH u O - alquilo C1-6 o, junto con R1 , puede representar = O; R8 representa H u OH; R10 representa alquilo C1-6, alquilo C1-6 sustituido con uno o más grupos hidroxi, alquenilo C2-6, alquenilo C2-6 sustituido con uno o más grupos hidroxi, o alquilo C1-6 sustituido con = O; X representa O, (H,OH) ó - CH2O -; Y representa O, (H,OH), N - NR11 R12 ó N- OR13 ; R11 y R12 , independientemente, representan H, alquilo C1-6, fenilo o tosilo; R13 representa H o alquilo C1-6; R20 y R 21 representan, independientemente, O, o pueden representar, independientemente, (R20 a,H) y (R 21 a,H), respectivamente; R20 a y R21 a representan, independientemente, OH, O - alquilo C1-6 u OCH2OCH2CH2OCH3; además, R20 a y R 21 a pueden representar juntos un átomo de oxígeno en un anillo de epóxido; R23 representa H; n es1 ó 2; además de sus significados anteriores, Y, R10 y R23 , juntoconlosátomos de carbono a los que están unidos, pueden representar un anillo heterocíclico de 5 o 6 miembros con contenido de N, S u O, que puede estar saturado o insaturado y que puede estar sustituido con uno o más grupos seleccionados de alquilo C1-6, hidroxi, alquilo C1-6 sustituido con uno o más grupo hidroxi, O - alquilo C1-6, bencilo y - CH2Se(C6H5); con la condición de que: (a) cuando [R3 y R4] y [R5 y R6] representan en cada caso un enlace carbono - carbono; R7 representa Ho un grupo OH; R8 representa H; R10 representa metilo, etilo, propilo o alilo; R20 a representa OCH3; y R21 a representa OH; entonces X e Y no representan ambos O; y (b) cuando [R1 y R 2 ] representandos átomos de hidrógeno vecinos; [R3 y R4 ] y[R5 y R 6 ] representan en cada caso un enlace carbono - carbono; R7 representa un grupo OH; R8 representa H; R10 representa alilo; R21 a representa OH; X e Y representan en cada caso O; y n es 2; entonces R20 no representa O ó (OH,H); y sus sales farmacéuticamente aceptables, que comprende: (a) producir un compuesto de fórmula I, en que uno o más de [R1 y R 2], [R3 y R4] ó [R5 y R6] representan dos átomos de hidrógeno vecinos, por reducción selectiva de un correspondiente grupo [R1 y R2], [R3 y R4] ó [R5 y R6] cuando representa un segundo enlace entre dos átomos de carbono vecinos en un correspondiente compuesto, (b) producir un compuesto de fórmula I, que contiene uno o más grupos hidroxi, por reducción selectiva deuno o más grupos C=O en un correspondiente compuesto, (c) producir un compuesto de fórmula I, que contiene un grupo C=C - C=O I OH por oxidación selectiva de un grupo C -C-C=O I OH en un correspondiente compuesto, (d) producir un compuesto de fórmula I, que contiene uno o más grupos alcoxi, por alquilación de uno o más grupos hidroxi en un correspondientecompuesto por reacción con un agente alquilante adecuado, (e) producir un compuesto de fórmula I, que contiene uno o más grupos hidroxilo, por desprotección de uno o más grupos hidroxi protegidos en un correspondiente compuesto en que el grupo protector se puede separar preferiblemente por hidrogenolisis, (f) producir un compuesto de fórmula I, que contiene un doble enlace carbono - carbono, por eliminación de HL a partir de un correspondiente compuesto en que L es un grupo lábil, (g) producir un compuesto de fórmula I, en que Y, R10 y R23 , junto con los átomos de carbono a los que están unidos, forman un anillo de tetrahidrofurano sustituido con un grupo CH2Se(C6H5), haciendo reaccionar un haluro de fenilselenilo con un correspondiente compuesto en el que Y es O y R10 es alilo, (h) producir un compuesto de fórmula I, que contiene un alcohol alílico, por oxidación selectiva de un grupo alilo en un correspondiente compuesto, (i) producir un compuesto de fórmula I, que contiene un grupo cetona, por oxidación de un grupo hidroxi en un correspondiente compuesto, (j) producir un compuesto de fórmula I, que contiene un diol vecino, por oxidación de un doble enlace carbono - carbono en un correspondiente compuesto, (k) producir un compuesto de fórmula I, que contiene un grupo aldehído, por escisión oxidante de un diol vecino en un correspondiente compuesto, (l) producir un compuesto de fórmula I, en que Y, R10 y R23 , junto con los átomos de carbono a los que están unidos, forman un anillo de pirrol, haciendo reaccionar amoníaco o una amina con un correspondiente compuesto, en que Y es O y R10 es - CH2CHO, (m) producir un compuesto de fórmula I, que contiene un grupo epóxido, por ciclación de un grupo **fórmula** en un correspondiente compuesto, (n) producir un compuesto de fórmula I, en que Y representa un grupo oxima, por reacción de un correspondiente compuesto en que Y es O, con una amina oxígeno - sustituida, (o) producir un compuesto de fórmula I, que contiene un grupo COCH3, por oxidación de un grupo alqueno terminal en un correspondiente compuesto, (p) producir un compuesto de fórmula I, en que X representa-CH2O - , por reacción de un correspondiente compuesto en que X es O, con diazometano, (q) producir un compuesto de fórmula I, en que Y es una hidrazona o un derivado de hidrazona, haciendo reaccionar un correspondiente compuesto en que Y es O, con hidrazina o una hidrazina sustituida.
ES89900628T 1987-12-09 1988-12-02 Compuestos macrociclicos. Expired - Lifetime ES2071681T3 (es)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GB878728821A GB8728821D0 (en) 1987-12-09 1987-12-09 Compounds
GB878728820A GB8728820D0 (en) 1987-12-09 1987-12-09 Compounds
GB888803373A GB8803373D0 (en) 1988-02-13 1988-02-13 Compound
GB888803377A GB8803377D0 (en) 1988-02-13 1988-02-13 Compound
GB888803370A GB8803370D0 (en) 1988-02-13 1988-02-13 Compound
GB888803375A GB8803375D0 (en) 1988-02-13 1988-02-13 Compound
GB888803371A GB8803371D0 (en) 1988-02-13 1988-02-13 Compound
GB888803374A GB8803374D0 (en) 1988-02-13 1988-02-13 Compound
GB888803372A GB8803372D0 (en) 1988-02-13 1988-02-13 Compound
GB888809174A GB8809174D0 (en) 1988-04-19 1988-04-19 Compounds
GB888817624A GB8817624D0 (en) 1988-07-23 1988-07-23 Compounds
GB888818426A GB8818426D0 (en) 1988-08-03 1988-08-03 Compounds

Publications (1)

Publication Number Publication Date
ES2071681T3 true ES2071681T3 (es) 1995-07-01

Family

ID=27583057

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89900628T Expired - Lifetime ES2071681T3 (es) 1987-12-09 1988-12-02 Compuestos macrociclicos.

Country Status (16)

Country Link
EP (2) EP0323042A1 (es)
JP (1) JP2799208B2 (es)
KR (1) KR900700494A (es)
CN (1) CN1033458A (es)
AT (1) ATE120466T1 (es)
AU (1) AU630866B2 (es)
CA (1) CA1339128C (es)
DE (1) DE3853477T2 (es)
DK (1) DK387889A (es)
ES (1) ES2071681T3 (es)
FI (1) FI90550C (es)
IE (1) IE66163B1 (es)
IL (1) IL88629A (es)
NO (1) NO893166D0 (es)
NZ (1) NZ227251A (es)
WO (1) WO1989005304A1 (es)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3275305D1 (en) * 1981-05-19 1987-03-05 Firmadoor Australia Pty Ltd Operator for a door
EP0349061B1 (en) * 1988-06-29 1995-03-29 Merck & Co. Inc. Immunosuppressant agent
US5290772A (en) * 1988-06-29 1994-03-01 Merck & Co., Inc. Immunosuppressant agent
ATE131536T1 (de) * 1988-08-01 1995-12-15 Fujisawa Pharmaceutical Co Fr-901154- und fr-901155-derivate, verfahren zu ihrer herstellung
EP0356399A3 (en) * 1988-08-26 1991-03-20 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
EP0358508A3 (en) * 1988-09-08 1991-03-20 Merck & Co. Inc. Novel immunosuppressant compound
GB2225576B (en) * 1988-11-29 1992-07-01 Sandoz Ltd Substituted azatricyclo derivatives and metabolites,their preparation and pharmaceutical compositions containing them
EP0378320A3 (en) * 1989-01-13 1990-11-28 Merck & Co. Inc. Microbial transformation product
EP0378317A3 (en) * 1989-01-13 1990-11-28 Merck & Co. Inc. Microbial transformation product of l-679,934
US4975372A (en) * 1989-01-13 1990-12-04 Merck & Co., Inc. Microbial transformation product of L-683,590
US5268370A (en) * 1989-01-13 1993-12-07 Merck & Co., Inc. Microbial transformation product of L-679,934
EP0388153B1 (en) * 1989-03-15 1994-12-28 Merck & Co. Inc. Immunosuppressant agent
EP0399579A1 (en) * 1989-04-21 1990-11-28 Merck & Co. Inc. Macrolides having immunosuppressive activity
US5068323A (en) * 1989-04-21 1991-11-26 Merck & Co., Inc. Thermally re-arranged FK-506 derivatives having immunosuppressant activity
US5138052A (en) * 1989-06-13 1992-08-11 Merck & Co., Inc. L-683,590 microbial transformation product
CA2018710A1 (en) * 1989-06-13 1990-12-13 Shieh-Shung T. Chen L-683,590 microbial transformation product
WO1990015805A1 (en) * 1989-06-14 1990-12-27 Sandoz Ltd Heteroatoms-containing tricyclic compounds
US5200411A (en) * 1989-06-14 1993-04-06 Sandoz, Ltd. Heteroatoms-containing tricyclic compounds
WO1991002736A1 (en) * 1989-08-18 1991-03-07 Fisons Plc Macrocyclic compounds
EP0413532A3 (en) * 1989-08-18 1991-05-15 Fisons Plc Macrocyclic compounds
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
US5215995A (en) * 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
NZ235991A (en) * 1989-11-09 1993-05-26 Sandoz Ltd Macrolide compounds and pharmaceutical compositions thereof
US5352671A (en) * 1989-11-09 1994-10-04 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
US5208228A (en) * 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
IE904050A1 (en) * 1989-11-13 1991-05-22 Merck & Co Inc Aminomacrolides and derivatives having immunosuppressive¹activity
GB8925797D0 (en) * 1989-11-15 1990-01-04 Fisons Plc Compositions
EP0444829A3 (en) * 1990-02-27 1992-06-03 Fisons Plc Immunosuppressive compounds
US5260301A (en) * 1990-03-01 1993-11-09 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical solution containing FK-506
US5064835A (en) * 1990-03-01 1991-11-12 Merck & Co., Inc. Hydroxymacrolide derivatives having immunosuppressive activity
US5296489A (en) * 1990-03-13 1994-03-22 Fisons Immunosuppressive macrocyclic compounds
JPH05505798A (ja) * 1990-03-13 1993-08-26 フアイソンズ・ピーエルシー 免疫抑制マクロ環状化合物
CA2040551A1 (en) * 1990-04-30 1991-10-31 Mark T. Goulet Deoxymacrolide derivatives having immunosuppressive activity
EP0533930A1 (en) * 1990-06-11 1993-03-31 Fujisawa Pharmaceutical Co., Ltd. Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease
US5643901A (en) * 1990-06-11 1997-07-01 Fujisawa Pharmaceutical Co., Ltd. Medicament for treating idiopathic thrombocytopenic purpura
GB9014136D0 (en) * 1990-06-25 1990-08-15 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
US5342935A (en) * 1990-06-25 1994-08-30 Merck & Co., Inc. Antagonists of immunosuppressive macrolides
US5210030A (en) * 1990-06-25 1993-05-11 Merck & Co., Inc. Process for selectively acylating immunomycin
US5190950A (en) * 1990-06-25 1993-03-02 Merck & Co., Inc. Antagonists of immunosuppressive macrolides
CA2044846A1 (en) * 1990-06-25 1991-12-26 Thomas R. Beattie Antagonists of immunosuppressive macrolides
GB9014681D0 (en) * 1990-07-02 1990-08-22 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
MY110418A (en) * 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
EP0466365A3 (en) 1990-07-03 1992-04-15 Merck & Co. Inc. Novel immunosuppressant fermentation products of a microorganism
GB9014881D0 (en) * 1990-07-05 1990-08-22 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
GB2245561A (en) * 1990-07-05 1992-01-08 Fujisawa Pharmaceutical Co Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
IE912886A1 (en) * 1990-08-18 1992-02-26 Fisons Plc Macrocyclic Compounds
GB2247620A (en) * 1990-09-07 1992-03-11 Fujisawa Pharmaceutical Co The use of macrolide compounds for cytomegalovirus infection
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
EP0480623A1 (en) * 1990-10-11 1992-04-15 Merck & Co. Inc. New halomacrolides and derivatives having immunosuppressive activity
GB2249027A (en) * 1990-10-23 1992-04-29 Fujisawa Pharmaceutical Co Use of macrolide compounds for hepatic failure
US5348966A (en) * 1990-10-24 1994-09-20 Fujisawa Pharmaceutical Co., Ltd. Method for treating pyoderma and Sezary's syndrome using FK 506 and related compounds
CA2054128A1 (en) * 1990-10-29 1992-04-30 Kevin M. Byrne Process for the production of analogues of immunomycin
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
GB2249787A (en) * 1990-11-19 1992-05-20 Fujisawa Pharmaceutical Co Lactone compounds
GB9027471D0 (en) * 1990-12-19 1991-02-06 Fujisawa Pharmaceutical Co Novel compound
GB2252041A (en) * 1991-01-23 1992-07-29 Fujisawa Pharmaceutical Co Use of macrolide compounds in treatment of autoimmune myocarditis
WO1992013862A1 (en) * 1991-02-05 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Lactone compounds
JPH06501026A (ja) * 1991-04-11 1994-01-27 ファイザー・インコーポレーテッド ストレプトミセス・ブレジェンシス由来の新規の免疫抑制剤
KR100237715B1 (ko) * 1991-04-26 2000-02-01 후지야마 아키라 안과질환에 대한 마크로라이드 화합물의 용도
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5250678A (en) 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
CA2071332A1 (en) * 1991-06-25 1992-12-26 Laszlo R. Treiber C-21 hydroxylated fk-506 antagonist
US5225403A (en) * 1991-06-25 1993-07-06 Merck & Co., Inc. C-21 hydroxylated FK-506 antagonist
US5149701A (en) * 1991-08-01 1992-09-22 Merck & Co., Inc. C-31 methylated FR-900520 cyclic hemiketal immunosuppressant agents
US5273979A (en) * 1991-08-01 1993-12-28 Merck & Co., Inc. C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5198358A (en) * 1991-08-28 1993-03-30 Merck & Co., Inc. Microorganism for producing C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
KR100351222B1 (ko) * 1991-09-05 2002-09-05 아보트 러보러터리즈 매크로사이클릭 면역 조절제 및 이의 제조방법
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
ZA926812B (en) 1991-09-09 1993-04-28 Merck & Co Inc O-heteroaryl,o-alkylheteroaryl,o-alkenylheteroaryl and o-alkynylheteroaryl macrolides having immunosupressive activity
US5252732A (en) * 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5817333A (en) * 1991-10-31 1998-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing a tricyclic compound
US5164399A (en) * 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
US5221625A (en) * 1992-01-10 1993-06-22 Merck & Co., Inc. Cyclcic FR-900520 microbial biotransformation agent
GB9203265D0 (en) * 1992-02-15 1992-04-01 Fisons Plc Pharmaceutically active compound
ATE153027T1 (de) * 1992-03-02 1997-05-15 Pfizer Zuckerderivate von makroliden
CA2091194A1 (en) * 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
US5284840A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
US5264355A (en) * 1992-07-02 1993-11-23 Merck & Co., Inc. Methlating enzyme from streptomyces MA6858
GB9218597D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
GB9218797D0 (en) * 1992-09-04 1992-10-21 Fisons Plc Pharmacologically active compounds
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
US5268282A (en) * 1992-09-28 1993-12-07 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5290689A (en) * 1992-09-28 1994-03-01 Merck & Co., Inc. New cyclic FR-900520 microbial biotransformation agent
US5283183A (en) * 1992-09-28 1994-02-01 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5268281A (en) * 1992-09-28 1993-12-07 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
DK0669127T3 (da) * 1992-11-18 1999-12-06 Fujisawa Pharmaceutical Co Farmaceutisk præparat med forlænget virkning
GB9227055D0 (en) * 1992-12-29 1993-02-24 Fujisawa Pharmaceutical Co New use
US5310901A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
US5310903A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
GB2279006A (en) * 1993-06-03 1994-12-21 Fujisawa Pharmaceutical Co Treatment of amyotrophic lateral sclerosis
US5359060A (en) * 1993-07-06 1994-10-25 Pfizer, Inc. Phosponated derivatives of macrolides
US5612350A (en) * 1993-11-30 1997-03-18 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements
US5880280A (en) * 1994-06-15 1999-03-09 Merck & Co., Inc. Aryl, alkyl, alkenyl and alkynylmacrolides having immunosuppressive activity
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
PL184750B1 (pl) 1994-10-26 2002-12-31 Novartis Ag Kompozycja w postaci emulsji do stosowania miejscowego
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
SI1064942T1 (en) 1998-03-26 2004-12-31 Fujisawa Pharmaceutical Co., Ltd. Sustained release preparation of a macrolide
IL142165A0 (en) 1998-10-02 2002-03-10 Kosan Biosciences Inc Polyketide synthase enzymes and recombinant dna constructs therefor
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US6569867B2 (en) 1999-10-01 2003-05-27 Kosan Biosciences, Inc. Polyketide derivatives
AR035411A1 (es) * 2000-12-29 2004-05-26 Fujisawa Pharmaceutical Co Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto
KR100512021B1 (ko) * 2002-07-25 2005-09-02 신득용 Fk506을 이용한 세포의 노화를 억제하는 방법 및 배양배지
AU2003901023A0 (en) * 2003-03-04 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. New use
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
CA2554045A1 (en) * 2004-01-20 2005-07-28 Astellas Pharma Inc. Method for treating erectile dysfunction
WO2007020853A1 (ja) 2005-08-12 2007-02-22 Astellas Pharma Inc. 薬剤の標的蛋白質を同定する方法及び標的蛋白質を用いた糖尿病治療薬のスクリーニング方法
JP2009203162A (ja) * 2006-06-05 2009-09-10 Astellas Pharma Inc マクロライド化合物の新規製造法
EP2457589A1 (en) 2006-08-31 2012-05-30 Astellas Pharma Inc. Reverse targeting lipid vesicle
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
EP2658855A2 (en) 2010-12-31 2013-11-06 Acies Bio d.o.o. Novel polyketide compounds and methods of making same
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3977995A1 (en) 2014-10-28 2022-04-06 Koushi Yamaguchi Tacrolimus for ameliorating pregnancy conditions
CN106074367A (zh) * 2016-07-20 2016-11-09 中山大学中山眼科中心 含fk506类化合物/fkbp蛋白二聚体的药物组合物及其制备方法
TW201821076A (zh) 2016-11-10 2018-06-16 瑞士商諾華公司 Bmp增強劑
EP3834826A4 (en) 2018-08-10 2022-07-27 Koushi Yamaguchi THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN THE MATERNO-FETAL RELATIONSHIP
US20220062245A1 (en) 2018-12-18 2022-03-03 Koushi Yamaguchi Agent for improving infertility, recurrent miscarriage, and state of pregnancy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
EP0349061B1 (en) * 1988-06-29 1995-03-29 Merck & Co. Inc. Immunosuppressant agent
ATE131536T1 (de) * 1988-08-01 1995-12-15 Fujisawa Pharmaceutical Co Fr-901154- und fr-901155-derivate, verfahren zu ihrer herstellung
EP0356399A3 (en) * 1988-08-26 1991-03-20 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP0346427B1 (en) 1995-03-29
JPH02502463A (ja) 1990-08-09
WO1989005304A1 (en) 1989-06-15
NZ227251A (en) 1990-02-26
FI90550C (fi) 1994-02-25
DK387889D0 (da) 1989-08-08
EP0346427A1 (en) 1989-12-20
AU2822889A (en) 1989-07-05
EP0323042A1 (en) 1989-07-05
FI893750A0 (fi) 1989-08-09
ATE120466T1 (de) 1995-04-15
IL88629A (en) 1994-04-12
IE66163B1 (en) 1995-12-13
CA1339128C (en) 1997-07-29
KR900700494A (ko) 1990-08-13
NO893166L (no) 1989-08-04
FI90550B (fi) 1993-11-15
JP2799208B2 (ja) 1998-09-17
CN1033458A (zh) 1989-06-21
IE883662L (en) 1989-06-09
DE3853477T2 (de) 1995-11-09
DK387889A (da) 1989-08-08
NO893166D0 (no) 1989-08-04
DE3853477D1 (de) 1995-05-04
AU630866B2 (en) 1992-11-12

Similar Documents

Publication Publication Date Title
ES2071681T3 (es) Compuestos macrociclicos.
EP0421634A3 (en) Bis(3,4-dialkylbenzylidene) sorbitol acetals and compositions containing same
HUT67691A (en) 7-(substituted)-8-(substituted)-9-[(substituted-glycyl)amido]6-demethyl-6-deoxytetracyclines, pharmaceutical compositions containing them and process to prepare them
IL114829A (en) Biphenyl isoxazole sulfonamide derivatives and pharmaceutical compositions containing the same
GR3014931T3 (en) Immunomodulatory azaspiranes.
ATE121939T1 (de) Ascorbinsäure-tocopheryl-phosphatdiester zur hemmung der maillard-reaktion.
ATE107875T1 (de) Wässrige polyurethan dispersionen.
HUT55032A (en) Process for producing 19-norsteroids comprising carbon chain substituted in 11beta position by amide or carbamagte group, as well as pharmaceutical compositions comprising such compounds as active ingredient
ATE161717T1 (de) Antivirale mittel
GR3007460T3 (es)
ATE110721T1 (de) 2-alkyl-3-benzoylbenzofurane und diese enthaltende pharmazeutische zusammensetzungen.
IL90724A0 (en) Novel esters and pharmaceutical compositions containing same
MX170732B (es) Composicion de derivados de succinimida y su uso
OA09349A (fr) "Nouveaux dérivés du 3-aminochromane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent".
ES2062406T3 (es) Nuevos compuestos de morfolinol, su preparacion y uso.
TW273555B (es)
EP0414391A3 (en) Aminoketone derivatives and use thereof
ZA835390B (en) 7-acylthio-15,16-methylene-3-oxo-17-pregna-1,4-diene 21,17-carbolactones,their preparation and use as medicinal agents
GR3017916T3 (en) 3,4-Disubstituted phenyl-heterocycles and their use.
NZ228803A (en) Sulphonanilides and anti-hypertensive compositions
ATE34176T1 (de) 2'-chloropentostatin, eine diese verbindung enthaltende pharmazeutische zusammensetzung und ein mikroorganismus zur herstellung dieser verbindung.
ATE93524T1 (de) Mitomycinanaloge, verfahren zu ihrer herstellung und pharmazeutische zubereitungen.
FI903511A0 (fi) Pyrrolo (2,1-b) tiazolderivat.
MY102247A (en) Phosphorylated acylglycosides, their preparation and use

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 346427

Country of ref document: ES